WHO ICTRP trial
Effect of Buspirone added to Typical Antipsychotics on Positive and Negative…
IRCT201106026691N1 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT201106026691N1 |
|---|---|
| Public title | Effect of Buspirone added to Typical Antipsychotics on Positive and Negative symptoms in schizophrenia |
| Scientific title | Effect of Buspirone added to Typical Antipsychotics on Positive and Negative symptoms in schizophrenia (a double blind, placebo controlled, randomized trial) |
| Primary sponsor | Mazandaran University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 3 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Schizophrenia. Schizophrenia;Schizophrenia |
| Interventions | Intervention 1: Typical Antipsychotics combined with Tablet Buspirone(30 mg/day) as intervention group for 6 weeks. Intervention 2: Typical Antipsychotics combined with Tablets placebo as control group for 6 weeks.;Treatment… |
| Registration date | Sep 17, 2012 |
| Target size | 50 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: